Table 3.
Gene alterations across UROMOL subclasses.
| Gene | 1/Luminal (n = 19) | 2/Luminal CIS-like (n = 20) | 3/Early basal-like (n = 11) | P |
|---|---|---|---|---|
| FGFR3 | 17 (89%) | 10 (50%) | 2 (18%) | <0.001 |
| KRAS | 1 | 2 | 0 | 0.8 |
| HRAS | 1 | 0 | 2 | 0.1 |
| ERBB2 | 0 | 4 (25%) | 4 (36%) | 0.02 |
| ERBB3 | 2 | 1 | 1 | 0.8 |
| PIK3CA | 5 | 3 | 4 | 0.4 |
| TSC1 | 1 | 4 | 1 | 0.4 |
| NF1 | 0 | 4 | 1 | 0.1 |
| TP53 | 2 | 5 | 4 | 0.3 |
| RB1 | 0 | 1 | 1 | 0.7 |
| MDM2 | 1 | 3 | 0 | 0.5 |
| CCND1 | 0 | 2 | 1 | 0.4 |
| CDKN2A | 3 | 7 | 2 | 0.3 |
| CDKN1A | 3 | 3 | 1 | 1 |
| STAG2 | 4 | 4 | 2 | 1 |
| KDM6A | 9 | 6 | 7 | 0.2 |
| ARID1A | 2 | 5 | 2 | 0.6 |
| KMT2A | 2 | 1 | 0 | 0.6 |
| KMT2C | 2 | 3 | 0 | 0.5 |
| KMT2D | 6 | 5 | 1 | 0.4 |
| EP300 | 4 | 1 | 2 | 0.3 |
| CREBBP | 1 | 5 | 1 | 0.2 |
| TERT | 12 (63%) | 20 (100%) | 9 (82%) | 0.007 |
| ERCC2 | 2 (11%) | 2 (10%) | 5 (45%) | 0.044 |
| ATM | 0 | 4 | 2 | 0.1 |
| BRCA1 | 0 | 2 | 0 | 0.3 |
| BRCA2 | 0 | 1 | 1 | 0.7 |
| TET2 | 0 | 1 (5%) | 3 (27%) | 0.03 |
| MGA | 1 | 3 | 0 | 0.5 |
| BCOR | 0 | 0 | 1 | 0.2 |
| BRD4 | 0 | 0 | 0 | 1 |
| DNAJB1 | 0 | 0 | 1 | 0.2 |
| IDH1 | 0 | 0 | 0 | 1 |
| JAK3 | 0 | 0 | 1 | 1 |
| ARID1B | 0 | 1 | 2 | 0.2 |
| BAP1 | 1 | 3 | 2 | 0.6 |
| PBRM1 | 2 | 2 | 0 | 0.6 |
| NFE2L2 | 0 | 1 | 0 | 1 |
| TBX3 | 1 | 0 | 0 | 0.6 |
| NCOR1 | 1 | 0 | 1 | 0.5 |
Note: Bold indicates statistical significance.
Abbreviation: CIS, carcinoma in situ.